Last reviewed · How we verify
NCT07112222
A Study of LM-350 in Subjects With Advanced Solid Tumours
Phase 1, PHASE2 trial testing LM-350 for injection in Malignant Tumors in 80 participants. Currently enrolling.
30 June 2028
Quick facts
| Lead sponsor | LaNova Medicines Limited |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 28 August 2025 |
| Primary completion | 30 June 2028 |
| Estimated completion | 30 June 2030 |
| Sites | 4 locations across China, Australia |
Drugs / interventions tested
- LM-350 for injection — full drug profile →
Conditions studied
- Malignant Tumors — all drugs for Malignant Tumors →
Sponsor
LaNova Medicines Limited — full company profile →
Who can join
18 and older, any sex, with Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07112222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Tumors
Currently open trials in the same condition.
- NCT07301801 — Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors · EARLY_PHASE1 · recruiting
- NCT07004244 — Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies · Phase 1 · recruiting
- NCT06944444 — A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT05714748 — Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors · Phase 1 · active not recruiting
- NCT05615974 — A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
Other LaNova Medicines Limited trials
Trials by the same sponsor.
- NCT07362186 — LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gast · Phase 3 · not yet recruiting
- NCT07387081 — Phase II Study of LM-24C5 · Phase 2 · recruiting
- NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06868199 — A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06873854 — A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07112222 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LaNova Medicines Limited
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07112222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing